If you are an invited speaker, please email your abstract to info@ihorizonsed.com by October 25, 2024 5:00 pm ET
ABSTRACT SUBMISSION INSTRUCTIONS
deadline: Monday September 23, 2022 at 5:00 pm ET
This year we are returning to an in-person program for HIV & Respi-DART 2024. You can use this link (coming soon) to submit an abstract for the HIV DART track or for the RespiDART track. If you are submitting more than one abstract, please fill out and submit a new form each time. Upon receiving your submission, your abstract will be reviewed by the Scientific Committee and if accepted, you will be invited to submit a PDF poster by Monday November 14, 2022 at 5pm EST.
All accepted abstracts will be made available to conference delegates as viewable PDF posters, accessible through the meeting website.
Guidelines
Use Arial font size 11 for your abstract
Please include a title in bold at the top of the abstract, this should be followed by list of authors and affiliations
All submitted abstracts should consist of background, methods, results, and conclusions
All text should flush to the left side of the page
Although there is no word limit to the abstract, we recommend a length of 500 words
If you choose to include figures, tables, or chemical structures in your abstract, please fit the abstract to one page (A4)
It is a requirement of participation in DART series conferences that all chemical structures be disclosed for investigational compounds that are presented at the virtual meeting, including oral abstracts, poster presentations, and invited speaker talks.
Please see below for an example of an abstract:
Categories for abstract submission:
For HIV-DART Track:
Aging and HIV
Animal models
Anti-HIV therapeutics and long-acting slow-release formulations
Clinical trials
Co-infections
Co-morbidities
Diagnostics
Drug development for non-SARS-CoV-2 respiratory viruses (influenza, RSV, etc.)
Drug resistance
Epidemiology and transmission
HIV cure
HIV drug development
Other: ______
For Respi-DART Track:
Long COVID
Microbiome
Non-respiratory emerging viruses (e.g., norovirus, dengue virus, chikungunya virus, yellow fever virus)
Public health
SARS-CoV-2 drug development: Clinical
SARS-CoV-2 drug development: Host-directed therapies
SARS-CoV-2 drug development: Pre-clinical
SARS-CoV-2 vaccine development
Vaccine development
Viral pathogenesis
Other: ______
Abstract publication
All accepted abstracts will be published in the electronic abstract book made available on November 29, 2024 at 4pm ET.